Pick Topic
Review Topic
List Experts
Examine Expert
Save Expert
  Site Guide ··   
Parkinson Disease: HELP
Articles by Yu-Xin Wang
Based on 2 articles published since 2010
(Why 2 articles?)
||||

Between 2010 and 2020, Yuxi Wang wrote the following 2 articles about Parkinson Disease.
 
+ Citations + Abstracts
1 Review Modulation of neuroinflammation by cysteinyl leukotriene 1 and 2 receptors: implications for cerebral ischemia and neurodegenerative diseases. 2020

Wang, Yuxi / Yang, Yi / Zhang, Siran / Li, Chengtan / Zhang, Lihui. ·Department of Pharmacology, Hangzhou Key Laboratory of Medical Neurobiology, School of Medicine, Hangzhou Normal University, Hangzhou, Zhejiang, China. · Department of Neurology, Zhejiang Hospital, Hangzhou, Zhejiang, China. · Department of Pharmacology, Hangzhou Key Laboratory of Medical Neurobiology, School of Medicine, Hangzhou Normal University, Hangzhou, Zhejiang, China. Electronic address: lhzhang@hznu.edu.cn. ·Neurobiol Aging · Pubmed #31986345.

ABSTRACT: Neuroinflammation is a complex biological process and has been known to play an important role in age-related cerebrovascular and neurodegenerative disorders, such as cerebral ischemia, Alzheimer's disease, and Parkinson's disease. Cysteinyl leukotrienes (CysLTs) are potent inflammatory lipid mediators that exhibit actions mainly through activating type 1 and type 2 CysLT receptors (CysLT1 and CysLT2). Accumulating evidence shows that CysLT1 and CysLT2 are activated at different stages of pathological process in various cell types in the brain such as vascular endothelial cells, astrocytes, microglia, and neurons in response to insults. However, the precise roles and mechanisms of CysLT1 and CysLT2 in regulating the pathogenesis of cerebral ischemia, Alzheimer's disease, and Parkinson's disease are not fully understood. In this article, we focus on current advances that link activation of CysLT1 and CysLT2 to the pathological process during brain ischemia and neurodegeneration and discuss mechanisms by which CysLT1 and CysLT2 mediate inflammatory process and brain injury. Multitarget anti-inflammatory potentials of CysLT1 and CysLT2 antagonism for neuroinflammation and brain injury will also be reviewed.

2 Review Genetics of Parkinson's disease and related disorders. 2018

Zhang, Pei-Lan / Chen, Yan / Zhang, Chen-Hao / Wang, Yu-Xin / Fernandez-Funez, Pedro. ·Department of Neurology, Tianjin Huanhu Hospital, Tianjin, China. · Department of Biomedical Sciences, University of Minnesota Medical School-Duluth Campus, Duluth, Minnesota, USA. ·J Med Genet · Pubmed #29151060.

ABSTRACT: Parkinson's disease (PD) is a complex and heterogeneous neurological condition characterised mainly by bradykinesia, resting tremor, rigidity and postural instability, symptoms that together comprise the parkinsonian syndrome. Non-motor symptoms preceding and following clinical onset are also helpful diagnostic markers revealing a widespread and progressive pathology. Many other neurological conditions also include parkinsonism as primary or secondary symptom, confounding their diagnosis and treatment. Although overall disease course and end-stage pathological examination single out these conditions, the significant overlaps suggest that they are part of a continuous disease spectrum. Recent genetic discoveries support this idea because mutations in a few genes (α-synuclein,